
Pharmacology Biochemistry and Behavior, Год журнала: 2024, Номер 245, С. 173906 - 173906
Опубликована: Ноя. 15, 2024
Язык: Английский
Pharmacology Biochemistry and Behavior, Год журнала: 2024, Номер 245, С. 173906 - 173906
Опубликована: Ноя. 15, 2024
Язык: Английский
Journal of Anesthesia and Translational Medicine, Год журнала: 2024, Номер 3(3), С. 65 - 75
Опубликована: Июль 11, 2024
Ketamine, a dissociative anesthetic, is widely utilized in both human and veterinary anesthesia. Its (S)-enantiomer, esketamine, similarly employed for anesthesia analgesia. The anesthetic effects of ketamine esketamine arise from their antagonism the N-methyl-D-aspartate receptor (NMDAR). In field psychiatry, rapid-acting antidepressant properties severe depression have generated significant interest, resulting its increased off-label usage United States (U.S.). 2019, nasal spray received approval use U.S. Europe. However, concerns emerged regarding potential adverse effects, including long-term efficacy, addiction risks, suicide risk clinical settings. contrast, arketamine, (R)-enantiomer ketamine, exhibits superior longer-lasting rodent models depression, with fewer side compared to esketamine. Nevertheless, research on efficacy safety arketamine patients remains limited. This article provides concise exploration historical two enantiomers while also delving into future directions application these fields.
Язык: Английский
Процитировано
11International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(12), С. 6804 - 6804
Опубликована: Июнь 20, 2024
NMDA receptor antagonists have potential for therapeutics in neurological and psychiatric diseases, including neurodegenerative epilepsy, traumatic brain injury, substance abuse disorder (SUD), major depressive (MDD). (S)-ketamine was the first of a novel class antidepressants, rapid-acting to be approved medical use. The stereoisomer, (R)-ketamine (arketamine), is currently under development treatment-resistant depression (TRD). compound has demonstrated efficacy multiple animal models. Two clinical studies disclosed TRD bipolar depression. A study by drug sponsor recently failed reach priori endpoints but post hoc analysis revealed efficacy. value supported experimental data humans rodents, showing that it less sedating, does not produce marked psychotomimetic or dissociative effects, than (S)-ketamine, produces models range disorders. mechanisms action antidepressant effects are hypothesized due antagonism and/or non-NMDA mechanisms. We suggest further experimentation with will create improved medicines some disorders underserved current medications.
Язык: Английский
Процитировано
9Journal of Affective Disorders, Год журнала: 2024, Номер 367, С. 745 - 755
Опубликована: Сен. 3, 2024
Chronic restrain stress (CRS) induces depression-like behaviors and demyelination in the brain; however, relationship between these remains unclear. Arketamine, (R)-enantiomer of ketamine, has shown rapid antidepressant-like effects CRS-exposed mice. We examined whether arketamine can improve both brains Additionally, we investigated role transforming growth factor β1 (TGF-β1) beneficial arketamine. A single dose (10 mg/kg) improved behavior corpus callosum Correlations were found this region. Furthermore, pretreatment with RepSox, an inhibitor TGF-β1 receptor, significantly blocked on Finally, a intranasal administration ameliorated The precise mechanisms by which contributes to remain These data suggest that CRS-induced may contribute behaviors, mitigate changes through TGF-β1-dependent mechanism.
Язык: Английский
Процитировано
6Research Square (Research Square), Год журнала: 2024, Номер unknown
Опубликована: Авг. 5, 2024
Язык: Английский
Процитировано
0Pharmacology Biochemistry and Behavior, Год журнала: 2024, Номер 245, С. 173906 - 173906
Опубликована: Ноя. 15, 2024
Язык: Английский
Процитировано
0